
Luye Pharma Group announced today that one of its key central nervous system (CNS) products, Rivastigmine Tran...

This regional initiative aims to raise mental health awareness, supporting patients, physicians and health sys...

Luye Pharma Group recently signed two agreements with partners in Latin America, boosting further development ...

To bring Mindfront Health’s EBM interdisciplinary diagnosis and treatment services to China

Requiring twice-weekly administration, the product further increases patient compliance and reduces the burden...

To provide additional beneficial treatment options for patients with Alzheimer’s